![]() | ![]() |
Formats:
|
||||||||||||||||||||
Copyright © 2005, American Society for Microbiology Regulation of NuA4 Histone Acetyltransferase Activity in Transcription and DNA Repair by Phosphorylation of Histone H4 Laval University Cancer Research Center, Hôtel-Dieu de Québec (CHUQ), Quebec City, QC, Canada G1R 2J6 *Corresponding author. Mailing address: Laval University Cancer Research Center, Hôtel-Dieu de Québec (CHUQ), 9 McMahon Street, Quebec City, QC, Canada G1R 2J6. Phone: (418) 525-4444, ext. 15545. Fax: (418) 691-5439. E-mail: Jacques.Cote/at/crhdq.ulaval.ca. †These authors contributed equally to this work Received April 15, 2005; Revised May 6, 2005; Accepted June 21, 2005. This article has been cited by other articles in PMC.Abstract The NuA4 complex is a histone H4/H2A acetyltransferase involved in transcription and DNA repair. While histone acetylation is important in many processes, it has become increasingly clear that additional histone modifications also play a crucial interrelated role. To understand how NuA4 action is regulated, we tested various H4 tail peptides harboring known modifications in HAT assays. While dimethylation at arginine 3 (R3M) had little effect on NuA4 activity, phosphorylation of serine 1 (S1P) strongly decreased the ability of the complex to acetylate H4 peptides. However, R3M in combination with S1P alleviates the repression of NuA4 activity. Chromatin from cells treated with DNA damage-inducing agents shows an increase in phosphorylation of serine 1 and a concomitant decrease in H4 acetylation. We found that casein kinase 2 phosphorylates histone H4 and associates with the Rpd3 deacetylase complex, demonstrating a physical connection between phosphorylation of serine 1 and unacetylated H4 tails. Chromatin immunoprecipitation experiments also link local phosphorylation of H4 with its deacetylation, during both transcription and DNA repair. Time course chromatin immunoprecipitation data support a model in which histone H4 phosphorylation occurs after NuA4 action during double-strand break repair at the step of chromatin restoration and deacetylation. These findings demonstrate that H4 phospho-serine 1 regulates chromatin acetylation by the NuA4 complex and that this process is important for normal gene expression and DNA repair. Posttranslational modifications of histone proteins in chromatin are a critical means of regulation for DNA-related processes in the cell. It has long been known that posttranslational modifications, such as acetylation, methylation, phosphorylation, and ubiquitination of histones, exist in the cell. While historically histone acetylation was the most widely studied for its correlation with active transcription, recent years have seen the emergence of roles for histone methylation, phosphorylation, and ubiquitination. It has become increasingly clear that each of these modifications or marks is intimately involved in the regulation of various cellular processes (52). Addition or removal of acetylation or phosphorylation alters the charge of their target residues, which may physically affect the interaction of histone tails with DNA, providing a more “open or closed” state. Alternatively, any of these marks might provide recognition sites for protein modules, as shown for the bromodomains of TAF1 (TAFII250) and Bdf1, which were shown to preferentially bind to multiply acetylated forms of histone H4, or the chromodomains of HP1 and Polycomb, which specifically bind to methylated lysine 9 or 27 on histone H3, respectively (18, 26, 31, 38). The histone N-terminal tails contain an extraordinarily high concentration of known and putative modification sites. To date, the most extensively studied region of histone modification is found in the histone H3 N-terminal tail. Phosphorylation of serine 10 of histone H3 has been associated with both mitotic condensation and gene activation by mitogenic factors. Interestingly, H3 peptides containing phospho-serine 10 potentiate acetylation of neighboring lysine 14 by several histone acetyltransferases (HATs), including Gcn5 (6, 35). However, this stimulation could not be reproduced in HAT assays using chromatin substrates and native SAGA complex (48). Nevertheless, this combination of two marks is associated with certain actively transcribed genes, including the immediate-early genes upon epidermal growth factor stimulation and also a subset of Gcn5-dependent genes in yeast (6, 35). As briefly mentioned above, methylation of lysine 9 on histone H3 is a docking point for HP1, a protein sufficient to nucleate repressive heterochromatin. Thus, it is interesting that methylation of lysine 9 is also refractory to phosphorylation of serine 10 (17). It is evident from these studies that neighboring histone modifications can directly affect one another (16, 17). Interestingly, this type of dynamic interplay can also be seen in trans. The ubiquitination of lysine 123 on the C terminus of histone H2B by Rad6 is required for the subsequent methylation of lysine 4 and lysine 79 on histone H3 (57), though the mechanism remains unknown. While most nuclear HATs target mainly nucleosomal histone H3, the NuA4 histone acetyltransferase complex acetylates lysine residues in the histone H4 tail (as well as H2A) (14). Little is known about the interplay of modifications on the histone H4 tail. We therefore set out to determine how the various modifications in the H4 tail affect the ability of NuA4 to acetylate. Here, we show that phosphorylation of serine 1 decreases the HAT function of NuA4 on H4 tail peptides. However, if arginine 3 is also dimethylated (R3M), NuA4 acetylation is recovered to levels seen on the unmodified H4 tail. Interestingly, S1 phosphorylation (S1P) is regulated in yeast. Under DNA damage conditions with increased levels of phospho-serine 1 (P-Ser1), there is a drop in acetylation of histone H4. However, blocking the cells in S phase also increases phosphorylation of serine 1 with no apparent loss of acetylation. Notably, casein kinase 2 (CK2), a DNA damage-regulated kinase, can phosphorylate histone H4 at serine 1 and is found associated with the Sin3/Rpd3 histone deacetylase complex, thus connecting phospho-serine 1 with loss of acetylation on histone H4. This is confirmed in vivo, as local increase of H4 phosphorylation correlates with its deacetylation during both gene transcription and DNA repair. MATERIALS AND METHODS Peptides. Synthetic peptides were synthesized corresponding to the N-terminal 19 or 25 residues of histone H4 with or without the following modifications: phospho-serine 1, dimethyl-arginine 3, and dimethyl-lysine 20. Peptides multiply acetylated at lysine 5, 8, 12, and/or 16 (25-mers) were a generous gift from Patrick Grant. Doubly and singly modified peptide combinations (22-mers) with phospho-serine 1, dimethyl-arginine 3, and acetyl-lysine 5 were kindly provided by C. D. Allis. All H4 peptides were N-terminally acetylated, as found in vivo, and verified by mass spectrometry after synthesis/purification to confirm the presence of the specific modifications. Protein purification and HAT, phosphatase, and kinase assays. Recombinant Esa1 was purified as described previously (15). Purified NuA4 was obtained either by conventional purification of yeast extracts over nickel agarose, mono Q, and superose 6 columns as described previously (1) or by tandem affinity purification (TAP) of tagged-Epl1 (5). HAT assays were performed as described previously (1). For peptide experiments, 300 ng of unmodified and various modified histone H4 N-terminal tail peptides were used as substrates. After liquid scintillation counting, values were normalized compared to unmodified peptide and are presented in bar graph form. Relative peptide amounts were verified by optical density (OD) and staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). All HAT assay experiments were repeated several times with similar results. The data presented are from a single experiment done in triplicate. For phosphatase assays, 300 ng phospho-serine 1 or unmodified peptide was incubated with 200 units of lambda phosphatase (New England Biotechnology) in conditions similar to HAT assays (50 mM Tris-HCl, pH 8, 5% glycerol, 0.5 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 mM dithiothreitol [DTT]) with 2 mM MnCl2 for 30 min at 30°C. In some cases, either prior to or after phosphatase, 0.5 mM sodium vanadate, a phosphatase inhibitor, was included in the reaction mixture. HAT reactions with Esa1 or NuA4 were performed in final conditions of 50 mM NaCl, 50 mM Tris-HCl, pH 8, 5% glycerol, 0.5 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 mM DTT, and 1.3 mM MnCl2. For kinase assays, reactions were carried out with 2 μg of histones (purified or recombinant) in final conditions of 80 mM NaCl/KCl, 25 mM Tris-HCl, pH 8, 10 mM MgCl2, 1 mM DTT, 50 μM cold ATP, and 1 μCi [γ-32P]ATP for 30 min at 30°C. Samples were run on 18% SDS-PAGE, blotted to nitrocellulose, dried, and exposed to film. For Western blots, assays were performed similarly except that the membranes were probed with anti-S1P antibody as described above. Sin3, Rpd3, and Ckb2 were purified by tandem affinity using TAP-tagged strains (Euroscarf) (20) as described previously (30). Yeast chromatin preparation and Western blot and dot blot analyses. Cells were grown in yeast-peptone-dextrose (YPD) until they reached an OD at 600 nm (OD600) of 1 to 1.2, at which point alpha factor (1 μM), nocodozole (10 μg/ml), hydroxyurea (HU) (200 mM), methyl methane-sulfonate (MMS) (0.05%), rapamycin (25 nM), or nothing (control) was added while growth continued for 2 h. For the stationary-phase condition, cells were stopped at an OD600 of 6 to 7. Native yeast chromatin was prepared as described previously (30). Equivalent amounts (2 μg) of purified chromatin were run in 18% SDS-PAGE, blotted to nitrocellulose, and probed overnight at 4°C with the following antihistone antibodies at 1:1,000 dilution unless otherwise indicated. From Upstate Biotechnology, α-phospho-S10 H3, α-dimethyl-K4 H3 (1:5,000), α-acetylated H3, α-dimethyl-R3 H4, α-hyperacetylated H4 (1:3,000) (cross-reacts with acetylated H2A), α-K8Ac H4, α-K12Ac H4, and α-H4 (1:250) were used, while α-K5Ac and α-K16Ac were obtained from Serotec. α-phospho-S1 H4 (1:2,000) was generously provided by C. D. Allis (3). α-phospho-S129 H2A (1:500) was a kind gift from Jessica Downs (13). Ponceau staining of the membrane was used to determine equivalent loading. For the epitope-blocking measurement (see Fig. Fig.4B),4B
Yeast strains, plasmid mutagenesis, and growth assays. Strain BY4741 from Resgen was used for purification of native chromatin. Yeast strain UCC1111, with both chromosomal copies of histone H3 and H4 deleted and harboring an episomal HHT2-HHF2 locus, and plasmid pMP3 were kindly provided by D. Gottschling (25). Histone H4 serine 1-to-alanine (S1A) or -glutamate (S1E) and arginine 3-to-alanine (R3A) or -glutamine (R3Q) mutations were introduced into pMP3 (ARS/CEN/TRP1), a plasmid containing the HHT2-HHF2 copy of histones H3 and H4, by PCR mutagenesis using the Stratagene QuickChange protocol. Plasmids were sequenced for the coding regions of both histones H3 and H4 and transformed into UCC1111. In order to aid removal of the WT ADE2 plasmid, transformants were grown for two cycles to an OD600 of at least 2.5 in synthetic dropout (SD) medium lacking tryptophan with 0.4 μg/ml adenine and plated on selective medium (SD Trp−), generating strains QY829 (WT), QY830 (S1A), QY831 (S1E), QY832 (R3A), and QY8733 (R3Q). For growth analysis, the WT and strains with histone H4 mutations were grown for two generations to an OD600 of 0.5 to 1 and diluted to an OD600 of 0.02, followed by four serial fivefold dilutions. These were plated on YPD, YPD plus 0.03% MMS, and YPD plus 130 mM HU and grown for 3 to 4 days at 30°C. ChIP assays. For real-time PCR analysis of chromatin immunoprecipitation (ChIP) experiments on the HSP104 gene, BY4741 cells were grown in YPD at 30°C until log phase and shifted to 39°C for 10 min (changed to prewarmed medium). The ChIP protocol was as described before (39). For the experiment at an HO-induced DNA double-strand break (see Fig. Fig.7),7
RESULTS Each conserved lysine residue of the histone H4 tail can be independently acetylated by Esa1 and NuA4. It was previously shown that Esa1 alone and as part of the NuA4 complex can acetylate all four of the acetylatable lysine residues in the H4 tail (1, 8, 40). We confirmed this by testing the abilities of these proteins to acetylate histone H4 tail peptides containing only one available lysine (K5, K8, K12, or K16) or the fully acetylated substrate (H4Ac) compared to the unmodified peptide (H4wt) (Fig. (Fig.1A).1A
Phosphorylation of serine 1 inhibits acetylation of the H4 N-terminal domain by Esa1 and NuA4. The first defined effect of one histone modification on another came from reports showing that histone H3 peptides phosphorylated at serine 10 are better substrates for acetylation of lysine 14 by several HATs, including Gcn5 (6, 9, 35). We wanted to investigate the effect of known histone H4 modifications on the ability of NuA4 to acetylate its target lysines in the histone H4 tail. Synthetic peptides corresponding to the N-terminal residues of histone H4 either without modification (H4) or containing phospho-serine at position 1 (S1P), dimethyl-arginine at position 3 (R3M), or dimethyl-lysine at position 20 (K20M) were subjected to HAT assays with Esa1 or NuA4 as shown in Fig. Fig.1A.1A NuA4 activity is recovered upon dephosphorylation of histone H4 at serine 1. To confirm this inhibitory effect of serine 1 phosphorylation, we carried out assays on the unmodified and phosphorylated peptides with lambda phosphatase. The order of addition of reagents is depicted in Fig. Fig.2A,2A
Methylation of histone H4 arginine 3 alleviates the inhibitory effect of phospho-serine 1 on NuA4 activity. In order to assess other possible consequences of multiple modifications on the H4 tail, we used 22-mer peptides containing the single modifications phospho-serine 1 (S1P), dimethyl-arginine 3 (R3M), or acetyl-lysine 5 (K5Ac) or double combinations of these marks. While Esa1 and NuA4 complex again showed decreased activity on phospho-serine 1 and little effect with methyl-arginine 3, they were also inhibited by acetyl-lysine 5 (Fig. (Fig.3).3
Phosphorylation of histone H4 at serine 1 is regulated in vivo. It was interesting that for histone H4, phosphorylation had a detrimental effect on acetylation by NuA4, whereas histone H3 phospho-serine 10 has been suggested to play a positive role in Gcn5-dependent acetylation (6, 35). In addition, the methylation of arginine 3 negates phospho-serine 1 inhibition. In light of this, we wanted to see if these modifications were regulated during the cell cycle and under certain cellular conditions. Yeast cells were grown to an OD600 of 1 to 1.2 and then treated with either alpha factor, which arrests cells in the G1 phase of the cell cycle; hydroxyurea, which arrests cells in S phase; nocodazole, which prevents the transition from G2 to M phase; MMS, which causes single- and double-strand breaks; rapamycin, which is an inhibitor of the TOR (target of rapamycin) pathway; or nothing (control) for a period of 2 hours. After isolation of nuclei, native chromatin was purified and samples were run in SDS-PAGE and blotted to nitrocellulose. When we assayed for the presence of modified histones by Western blotting, we observed striking variability in the levels of serine 1 phosphorylation, as well as in acetylation of histone H4 (Fig. (Fig.4A).4A However, phospho-serine 1 is also stimulated in the presence of hydroxyurea, while a concomitant decrease in histone H4 acetylation is not observed. This does not accord with our theory that phosphorylation of serine 1 is inhibitory to acetylation of the H4 tail. However, H2A phospho-serine 129 is not induced in these conditions, indicating that at least in this case, H4 serine 1 phosphorylation is not a consequence of DNA damage. There was also no apparent increase in dimethylation of arginine 3 in HU-treated cells, which could have explained the apparent simultaneous increase of H4 phosphorylation/acetylation (since R3M counteracts the inhibitory effect of S1P on NuA4-dependent acetylation [Fig. [Fig.3]).3 Mutation of histone H4 at serine 1 does not cause sensitivity to MMS or hydroxyurea. Phosphorylation of histone H2A at serine 129 is induced in MMS, and mutation of this residue causes MMS sensitivity (13). Since an increase in phospho-serine 1 on histone H4 was also brought on during MMS treatment, we wondered if mutation of this residue in yeast cells would also provoke sensitivity to this DNA-damaging agent. Site-directed mutagenesis was performed on a plasmid encoding histones H3 and H4. Mutations at serine 1 and arginine 3 were used to generate strains expressing wild-type histone H3 and histone H4 harboring these altered residues. These cells were then subjected to growth assays on YPD in the absence or presence of MMS or hydroxyurea (Fig. (Fig.5A).5A
The Rpd3 histone deacetylase is physically linked to a histone H4 serine 1 kinase. If phosphorylation of H4 serine 1 is functionally linked to DNA damage response and blocking nucleosomal H4 acetylation, we would expect the responsible kinase to be regulated by DNA damage and to be linked to histone deacetylation. We tested a large number of kinases involved in DNA damage response, including Mec1, Tel1, Rad9, Dun1, Chk1, Rad53, and Hrr25, but their mutation had no significant effect on the MMS-induced H4 P-Ser1 signal (data not shown). Interestingly, independent yeast proteomic studies showed that affinity-purified Sin3/Rpd3 histone deacetylase complexes were found associated with the casein kinase II tetramer (Cka1/2 and Ckb1/2) (20, 22). Furthermore, CK2 was shown to be involved in the cellular response to DNA damage, including MMS treatment (21, 24, 27, 36, 37). In light of this, we decided to test tandem affinity-purified Rpd3 in a histone kinase assay. When wild-type yeast histones were incubated with purified Rpd3 complex in the presence of [γ-32P]ATP, histones H3 and H4 were phosphorylated (Fig. (Fig.5B,5B Phosphorylation of histone H4 Ser1 is linked to transcription. Yeast proteomic studies have found CK2 associated not only with purified Sin3/Rpd3 but even histones themselves, and also various proteins implicated in transcription (Fig. (Fig.6A)6A
Histone H4 serine 1 is phosphorylated near sites of DNA damage in vivo. We have shown that nucleosomal H4 P-Ser1 signals are induced in vivo when cells are treated with DNA damage-inducing agents like MMS (Fig. (Fig.4A).4A DISCUSSION Gaining insight into the mechanisms of communication between regulatory proteins/enzymes that modify or interact with the highly conserved histones is crucial to understanding all levels of DNA-related processes in the cell. It is becoming evident that the local environment of histone modifications is an important factor in dictating which interactions can and will occur. Inherent in this idea are the effects that the various modifications have on structure. Whether it is the general effect of loss of positive charge by acetylation causing loosening of the DNA or a specific local effect, such as phosphorylation of serine 10 on histone H3 affecting or being affected by lysine acetylation/methylation on the same tail, interrelatedness is a key. In addition, certain protein modules, such as bromodomains and chromodomains, have been shown to interact with acetylated lysines and methylated lysines, respectively, in a specific manner. It was shown that serine 10 phosphorylation on histone H3 is associated with increased acetylation at lysine 14 and transcription activation of a subset of genes (6, 34, 35). In contrast, for the histone H4 tail, our studies demonstrated that phosphorylation of serine 1 has a negative effect on acetylation by NuA4 in vitro. Interestingly, methyl-arginine 3 abrogates this phospho-serine 1 inhibition, though by itself this methylation has little effect on NuA4 acetylation in our peptide assays. On the other hand, methylation of the arginine 3 of histone H4 was previously shown to increase acetylation by human CBP in vitro (independently of other modifications) (53). While PRMT1 was shown to be the enzyme responsible for methylating arginine 3 of histone H4 in mammalian cells, deletion of the yeast homolog Hmt1/Rmt1 does not cause loss of methylation on this residue (30). This suggests that either another protein is responsible for Arg3 methylation in yeast or Hmt1/Rmt1 shares redundant functions with another methyltransferase. Nevertheless, several studies firmly linked mammalian PRMT1 to gene activation in the chromatin context (2, 28, 43, 53). In addition, yeast Hmt1/Rmt1 is recruited to specific genes in vivo during the beginning of the transcription elongation process (55). Recently, an enzyme able to regulate H4 Me-Arg3 levels in vivo by deimination was identified and linked to transcription downregulation (10, 54). Another point of note is that mammalian histone H2A has the same first five amino acids as H4 and can undergo the same modifications on serine 1, arginine 3, and lysine 5 (3, 30, 46, 50). The protein sequence of both the H2A.Z variant and the Tetrahymena H4 tail has an alanine substituted for the usual serine at position 1. This substitution is accompanied by a loss of arginine 3, suggesting that in the absence of serine 1, there is no requirement for arginine 3 (16, 50). Taking this into account with our peptide data, it will be interesting to see whether the role of arginine 3 methylation is somehow related to phosphorylation of serine 1. A critical way to elucidate this relationship will be to obtain antibodies raised against the doubly modified H4 peptide (P-Ser1/diMe-Arg3). In our analysis of native chromatin, we observed that several nuclear histone modifications, including phosphorylation, acetylation, and methylation of histone H4, are regulated throughout the cell cycle or upon exposure to drugs. After treatment with MMS, which introduces single- and double-strand breaks in DNA, phospho-serine 1 increases while acetylation of histone H4 decreases at lysines 5, 8, and 12 compared to control chromatin. This supports our theory that phospho-serine 1 is inhibitory to acetylation on the histone H4 tail. However, in the case of hydroxyurea-treated cells (blocked in S phase), isolated chromatin was found to have higher levels of phospho-serine 1 with no accompanying decrease in histone H4 acetylation. This discrepancy could be explained as follows. One possibility is that the remaining acetylation exists on different H4 tails than those with the phosphorylated serine. However, considering that modification of neighboring residues can greatly affect the function of an antibody by altering the epitope (Fig. (Fig.4B),4B Histone H4 serine 1 and arginine 3 mutants display no obvious growth phenotype and no sensitivity to the DNA-damaging agent MMS (Fig. (Fig.5),5 Maintenance of genome integrity is another critical nuclear process. The fact that H4 P-Ser1 is directly involved at sites of DNA double-strand breaks in addition to its role in gene transcription indicates that this specific chromatin modification is important in diverse nuclear functions. In a separate study, we previously showed that NuA4 binds to histone H2A phosphorylated on Ser129 near a double-strand break, allowing acetylation of the surrounding chromatin (12). We have now found that histone H4 is phosphorylated at a later stage, after DNA break formation and induction of the damage response (Fig. (Fig.7).7
In our previous work on the NuA4 HAT complex, we were surprised to find no major variation in its abundance and specific activity during the cell cycle and under other growth conditions (N. Lacoste and J. Côté, unpublished data). In this report, we demonstrate a new efficient way to regulate NuA4 acetyltransferase activity, i.e., through other posttranslational covalent modifications of its substrate, the histone H4 N-terminal domain. These findings add an important new circuitry to the cross talk that occurs between different histone modifications in chromatin and their diverse functional consequences. It also shows how NuA4-dependent acetylation is tightly regulated in vivo, at sites of both gene transcription and DNA repair. Acknowledgments We are indebted to C. D. Allis for providing anti-H4 P-Ser1 antibodies and the peptides with dual modifications. We are also grateful to Jessica Downs and Steve Jackson for anti-H2A P-Ser129, Patrick Grant and Jerry Workman for the peptides with a single available lysine, Luc Gaudreau for recombinant yeast histone H4, and Jim Haber for the JKM179 strain. We also thank D. Allis, S. Cheung, F. Turner, and C. Peterson for sharing results before publication and for encouragement. This work was supported by a grant from the Canadian Institutes of Health Research (CIHR). R.T.U. was a CIHR postdoctoral fellow. O.J.-R. holds a CIHR/Canada Graduate Scholarship, and J.C. is a CIHR Investigator. REFERENCES 1. Allard, S., R. T. Utley, J. Savard, A. Clarke, P. Grant, C. J. Brandl, L. Pillus, J. L. Workman, and J. Côté. 1999. NuA4, an essential transcription adaptor/histone H4 acetyltransferase complex containing Esa1p and the ATM-related cofactor Tra1p. EMBO J. 18:5108-5119. [PubMed] 2. An, W., J. Kim, and R. G. Roeder. 2004. Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53. Cell 117:735-748. [PubMed] 3. Barber, C. M., F. B. Turner, Y. Wang, K. Hagstrom, S. D. Taverna, S. Mollah, B. Ueberheide, B. J. Meyer, D. F. Hunt, P. Cheung, and C. D. Allis. 2004. The enhancement of histone H4 and H2A serine 1 phosphorylation during mitosis and S-phase is evolutionarily conserved. Chromosoma 112:360-371. [PubMed] 4. Bird, A. W., D. Y. Yu, M. G. Pray-Grant, Q. Qiu, K. E. Harmon, P. C. Megee, P. A. Grant, M. M. Smith, and M. F. Christman. 2002. Acetylation of histone H4 by Esa1 is required for DNA double-strand break repair. Nature 419:411-415. [PubMed] 5. Boudreault, A. A., D. Cronier, W. Selleck, N. Lacoste, R. T. Utley, S. Allard, J. Savard, W. S. Lane, S. Tan, and J. Côté. 2003. Yeast enhancer of polycomb defines global Esa1-dependent acetylation of chromatin. Genes Dev. 17:1415-1428. [PubMed] 6. Cheung, P., K. G. Tanner, W. L. Cheung, P. Sassone-Corsi, J. M. Denu, and C. D. Allis. 2000. Synergistic coupling of histone H3 phosphorylation and acetylation in response to epidermal growth factor stimulation. Mol. Cell 5:905-915. [PubMed] 7. Cheung, W. L., F. B. Turner, T. Krishnamoorthy, B. Wolner, S. H. Ahn, M. Foley, J. A. Dorsey, C. L. Peterson, S. L. Berger, and C. D. Allis. 2005. Phosphorylation of histone H4 serine 1 during DNA damage requires casein kinase II in S. cerevisiae. Curr. Biol. 15:656-660. [PubMed] 8. Clarke, A. S., J. E. Lowell, S. J. Jacobson, and L. Pillus. 1999. Esa1p is an essential histone acetyltransferase required for cell cycle progression. Mol. Cell. Biol. 19:2515-2526. [PubMed] 9. Clements, A., A. N. Poux, W. S. Lo, L. Pillus, S. L. Berger, and R. Marmorstein. 2003. Structural basis for histone and phosphohistone binding by the GCN5 histone acetyltransferase. Mol. Cell 12:461-473. [PubMed] 10. Cuthbert, G. L., S. Daujat, A. W. Snowden, H. Erdjument-Bromage, T. Hagiwara, M. Yamada, R. Schneider, P. D. Gregory, P. Tempst, A. J. Bannister, and T. Kouzarides. 2004. Histone deimination antagonizes arginine methylation. Cell 118:545-553. [PubMed] 11. Deckert, J., and K. Struhl. 2001. Histone acetylation at promoters is differentially affected by specific activators and repressors. Mol. Cell. Biol. 21:2726-2735. [PubMed] 12. Downs, J. A., S. Allard, O. Jobin-Robitaille, A. Javaheri, A. Auger, N. Bouchard, S. J. Kron, S. P. Jackson, and J. Côté. 2004. Binding of chromatin modifying activities to phosphorylated histone H2A at DNA damage sites. Mol. Cell 16:979-990. [PubMed] 13. Downs, J. A., N. F. Lowndes, and S. P. Jackson. 2000. A role for Saccharomyces cerevisiae histone H2A in DNA repair. Nature 408:1001-1004. [PubMed] 14. Doyon, Y., and J. Côté. 2004. The highly conserved and multifunctional NuA4 HAT complex. Curr. Opin. Genet. Dev. 14:147-154. [PubMed] 15. Eisen, A., R. T. Utley, A. Nourani, S. Allard, P. Schmidt, W. S. Lane, J. C. Lucchesi, and J. Côté. 2001. The yeast NuA4 and Drosophila MSL complexes contain homologous subunits important for transcription regulation. J. Biol. Chem. 276:3484-3491. [PubMed] 16. Fischle, W., Y. Wang, and C. D. Allis. 2003. Binary switches and modification cassettes in histone biology and beyond. Nature 425:475-479. [PubMed] 17. Fischle, W., Y. Wang, and C. D. Allis. 2003. Histone and chromatin cross-talk. Curr. Opin. Cell Biol. 15:172-183. [PubMed] 18. Fischle, W., Y. Wang, S. A. Jacobs, Y. Kim, C. D. Allis, and S. Khorasanizadeh. 2003. Molecular basis for the discrimination of repressive methyl-lysine marks in histone H3 by Polycomb and HP1 chromodomains. Genes Dev. 17:1870-1881. [PubMed] 19. Galasinski, S. C., D. F. Louie, K. K. Gloor, K. A. Resing, and N. G. Ahn. 2002. Global regulation of post-translational modifications on core histones. J. Biol. Chem. 277:2579-2588. [PubMed] 20. Gavin, A. C., M. Bosche, R. Krause, P. Grandi, M. Marzioch, A. Bauer, J. Schultz, J. M. Rick, A. M. Michon, C. M. Cruciat, M. Remor, C. Hofert, M. Schelder, M. Brajenovic, H. Ruffner, A. Merino, K. Klein, M. Hudak, D. Dickson, T. Rudi, V. Gnau, A. Bauch, S. Bastuck, B. Huhse, C. Leutwein, M. A. Heurtier, R. R. Copley, A. Edelmann, E. Querfurth, V. Rybin, G. Drewes, M. Raida, T. Bouwmeester, P. Bork, B. Seraphin, B. Kuster, G. Neubauer, and G. Superti-Furga. 2002. Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature 415:141-147. [PubMed] 21. Ghavidel, A., and M. C. Schultz. 2001. TATA binding protein-associated CK2 transduces DNA damage signals to the RNA polymerase III transcriptional machinery. Cell 106:575-584. [PubMed] 22. Ho, Y., A. Gruhler, A. Heilbut, G. D. Bader, L. Moore, S. L. Adams, A. Millar, P. Taylor, K. Bennett, K. Boutilier, L. Yang, C. Wolting, I. Donaldson, S. Schandorff, J. Shewnarane, M. Vo, J. Taggart, M. Goudreault, B. Muskat, C. Alfarano, D. Dewar, Z. Lin, K. Michalickova, A. R. Willems, H. Sassi, P. A. Nielsen, K. J. Rasmussen, J. R. Andersen, L. E. Johansen, L. H. Hansen, H. Jespersen, A. Podtelejnikov, E. Nielsen, J. Crawford, V. Poulsen, B. D. Sorensen, J. Matthiesen, R. C. Hendrickson, F. Gleeson, T. Pawson, M. F. Moran, D. Durocher, M. Mann, C. W. Hogue, D. Figeys, and M. Tyers. 2002. Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry. Nature 415:180-183. [PubMed] 23. Jazayeri, A., A. D. McAinsh, and S. P. Jackson. 2004. Saccharomyces cerevisiae Sin3p facilitates DNA double-strand break repair. Proc. Natl. Acad. Sci. USA 101:1644-1649. [PubMed] 24. Keller, D. M., X. Zeng, Y. Wang, Q. H. Zhang, M. Kapoor, H. Shu, R. Goodman, G. Lozano, Y. Zhao, and H. Lu. 2001. A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. Mol. Cell 7:283-292. [PubMed] 25. Kelly, T. J., S. Qin, D. E. Gottschling, and M. R. Parthun. 2000. Type B histone acetyltransferase Hat1p participates in telomeric silencing. Mol. Cell. Biol. 20:7051-7058. [PubMed] 26. Khorasanizadeh, S. 2004. The nucleosome: from genomic organization to genomic regulation. Cell 116:259-272. [PubMed] 27. Koch, C. A., R. Agyei, S. Galicia, P. Metalnikov, P. O'Donnell, A. Starostine, M. Weinfeld, and D. Durocher. 2004. Xrcc4 physically links DNA end processing by polynucleotide kinase to DNA ligation by DNA ligase IV. EMBO J. 23:3874-3885. [PubMed] 28. Koh, S. S., D. Chen, Y. H. Lee, and M. R. Stallcup. 2001. Synergistic enhancement of nuclear receptor function by p160 coactivators and two coactivators with protein methyltransferase activities. J. Biol. Chem. 276:1089-1098. [PubMed] 29. Krogan, N. J., M. Kim, S. H. Ahn, G. Zhong, M. S. Kobor, G. Cagney, A. Emili, A. Shilatifard, S. Buratowski, and J. F. Greenblatt. 2002. RNA polymerase II elongation factors of Saccharomyces cerevisiae: a targeted proteomics approach. Mol. Cell. Biol. 22:6979-6992. [PubMed] 30. Lacoste, N., R. T. Utley, J. M. Hunter, G. G. Poirier, and J. Côté. 2002. Disruptor of telomeric silencing-1 is a chromatin-specific histone H3 methyltransferase. J. Biol. Chem. 277:30421-30424. [PubMed] 31. Ladurner, A. G., C. Inouye, R. Jain, and R. Tjian. 2003. Bromodomains mediate an acetyl-histone encoded antisilencing function at heterochromatin boundaries. Mol. Cell 11:365-376. [PubMed] 32. Lee, S. E., F. Paques, J. Sylvan, and J. E. Haber. 1999. Role of yeast SIR genes and mating type in directing DNA double-strand breaks to homologous and non-homologous repair paths. Curr. Biol. 9:767-770. [PubMed] 33. Liang, G., J. C. Lin, V. Wei, C. Yoo, J. C. Cheng, C. T. Nguyen, D. J. Weisenberger, G. Egger, D. Takai, F. A. Gonzales, and P. A. Jones. 2004. Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome. Proc. Natl. Acad. Sci. USA 101:7357-7362. [PubMed] 34. Lo, W. S., L. Duggan, N. C. Emre, R. Belotserkovskya, W. S. Lane, R. Shiekhattar, and S. L. Berger. 2001. Snf1—a histone kinase that works in concert with the histone acetyltransferase Gcn5 to regulate transcription. Science 293:1142-1146. [PubMed] 35. Lo, W. S., R. C. Trievel, J. R. Rojas, L. Duggan, J. Y. Hsu, C. D. Allis, R. Marmorstein, and S. L. Berger. 2000. Phosphorylation of serine 10 in histone H3 is functionally linked in vitro and in vivo to Gcn5-mediated acetylation at lysine 14. Mol. Cell 5:917-926. [PubMed] 36. Loizou, J. I., S. F. El-Khamisy, A. Zlatanou, D. J. Moore, D. W. Chan, J. Qin, S. Sarno, F. Meggio, L. A. Pinna, and K. W. Caldecott. 2004. The protein kinase CK2 facilitates repair of chromosomal DNA single-strand breaks. Cell 117:17-28. [PubMed] 37. Luo, H., D. W. Chan, T. Yang, M. Rodriguez, B. P. Chen, M. Leng, J. J. Mu, D. Chen, Z. Songyang, Y. Wang, and J. Qin. 2004. A new XRCC1-containing complex and its role in cellular survival of methyl methanesulfonate treatment. Mol. Cell. Biol. 24:8356-8365. [PubMed] 38. Matangkasombut, O., and S. Buratowski. 2003. Different sensitivities of bromodomain factors 1 and 2 to histone H4 acetylation. Mol. Cell 11:353-363. [PubMed] 39. Nourani, A., R. T. Utley, S. Allard, and J. Côté. 2004. Recruitment of the NuA4 complex poises the PHO5 promoter for chromatin remodeling and activation. EMBO J. 23:2597-2607. [PubMed] 40. Ohba, R., D. J. Steger, J. E. Brownell, C. A. Mizzen, R. G. Cook, J. Côté, J. L. Workman, and C. D. Allis. 1999. A novel H2A/H4 nucleosomal histone acetyltransferase in Tetrahymena thermophila. Mol. Cell. Biol. 19:2061-2068. [PubMed] 41. Peterson, C. L., and J. Côté. 2004. Cellular machineries for chromosomal DNA repair. Genes Dev. 18:602-616. [PubMed] 42. Reid, J. L., Z. Moqtaderi, and K. Struhl. 2004. Eaf3 regulates the global pattern of histone acetylation in Saccharomyces cerevisiae. Mol. Cell. Biol. 24:757-764. [PubMed] 43. Rezai-Zadeh, N., X. Zhang, F. Namour, G. Fejer, Y. D. Wen, Y. L. Yao, I. Gyory, K. Wright, and E. Seto. 2003. Targeted recruitment of a histone H4-specific methyltransferase by the transcription factor YY1. Genes Dev. 17:1019-1029. [PubMed] 44. Roh, T. Y., W. C. Ngau, K. Cui, D. Landsman, and K. Zhao. 2004. High-resolution genome-wide mapping of histone modifications. Nat. Biotechnol. 22:1013-1016. [PubMed] 45. Ruiz-Carrillo, A., L. J. Wangh, and V. G. Allfrey. 1975. Processing of newly synthesized histone molecules. Science 190:117-128. [PubMed] 46. Sarmento, O. F., L. C. Digilio, Y. Wang, J. Perlin, J. C. Herr, C. D. Allis, and S. A. Coonrod. 2004. Dynamic alterations of specific histone modifications during early murine development. J. Cell Sci. 117:4449-4459. [PubMed] 47. Sawa, C., E. Nedea, N. Krogan, T. Wada, H. Handa, J. Greenblatt, and S. Buratowski. 2004. Bromodomain factor 1 (Bdf1) is phosphorylated by protein kinase CK2. Mol. Cell. Biol. 24:4734-4742. [PubMed] 48. Shogren-Knaak, M. A., C. J. Fry, and C. L. Peterson. 2003. A native peptide ligation strategy for deciphering nucleosomal histone modifications. J. Biol. Chem. 278:15744-15748. [PubMed] 49. Shroff, R., A. Arbel-Eden, D. Pilch, G. Ira, W. M. Bonner, J. H. Petrini, J. E. Haber, and M. Lichten. 2004. Distribution and dynamics of chromatin modification induced by a defined DNA double-strand break. Curr. Biol. 14:1703-1711. [PubMed] 50. Strahl, B. D., S. D. Briggs, C. J. Brame, J. A. Caldwell, S. S. Koh, H. Ma, R. G. Cook, J. Shabanowitz, D. F. Hunt, M. R. Stallcup, and C. D. Allis. 2001. Methylation of histone H4 at arginine 3 occurs in vivo and is mediated by the nuclear receptor coactivator PRMT1. Curr. Biol. 11:996-1000. [PubMed] 51. Tsai, S. C., and E. Seto. 2002. Regulation of histone deacetylase 2 by protein kinase CK2. J. Biol. Chem. 277:31826-31833. [PubMed] 52. Vaquero, A., A. Loyola, and D. Reinberg. 2003. The constantly changing face of chromatin. Sci. Aging Knowledge Environ. 2003:RE4. [PubMed] 53. Wang, H., Z. Q. Huang, L. Xia, Q. Feng, H. Erdjument-Bromage, B. D. Strahl, S. D. Briggs, C. D. Allis, J. Wong, P. Tempst, and Y. Zhang. 2001. Methylation of histone H4 at arginine 3 facilitating transcriptional activation by nuclear hormone receptor. Science 293:853-857. [PubMed] 54. Wang, Y., J. Wysocka, J. Sayegh, Y. H. Lee, J. R. Perlin, L. Leonelli, L. S. Sonbuchner, C. H. McDonald, R. G. Cook, Y. Dou, R. G. Roeder, S. Clarke, M. R. Stallcup, C. D. Allis, and S. A. Coonrod. 2004. Human PAD4 regulates histone arginine methylation levels via demethylimination. Science 306:279-283. [PubMed] 55. Yu, M. C., F. Bachand, A. E. McBride, S. Komili, J. M. Casolari, and P. A. Silver. 2004. Arginine methyltransferase affects interactions and recruitment of mRNA processing and export factors. Genes Dev. 18:2024-2035. [PubMed] 56. Zhang, X., Y. Ozawa, H. Lee, Y. D. Wen, T. H. Tan, B. E. Wadzinski, and E. Seto. 2005. Histone deacetylase 3 (HDAC3) activity is regulated by interaction with protein serine/threonine phosphatase 4. Genes Dev. 19:827-839. [PubMed] 57. Zhang, Y. 2003. Transcriptional regulation by histone ubiquitination and deubiquitination. Genes Dev. 17:2733-2740. [PubMed] |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||
Sci Aging Knowledge Environ. 2003 Apr 9; 2003(14):RE4.
[Sci Aging Knowledge Environ. 2003]Genes Dev. 2003 Aug 1; 17(15):1870-81.
[Genes Dev. 2003]Cell. 2004 Jan 23; 116(2):259-72.
[Cell. 2004]Mol Cell. 2003 Feb; 11(2):365-76.
[Mol Cell. 2003]Mol Cell. 2003 Feb; 11(2):353-63.
[Mol Cell. 2003]Mol Cell. 2000 Jun; 5(6):905-15.
[Mol Cell. 2000]Mol Cell. 2000 Jun; 5(6):917-26.
[Mol Cell. 2000]J Biol Chem. 2003 May 2; 278(18):15744-8.
[J Biol Chem. 2003]Curr Opin Cell Biol. 2003 Apr; 15(2):172-83.
[Curr Opin Cell Biol. 2003]Nature. 2003 Oct 2; 425(6957):475-9.
[Nature. 2003]Genes Dev. 2003 Nov 15; 17(22):2733-40.
[Genes Dev. 2003]Curr Opin Genet Dev. 2004 Apr; 14(2):147-54.
[Curr Opin Genet Dev. 2004]J Biol Chem. 2001 Feb 2; 276(5):3484-91.
[J Biol Chem. 2001]EMBO J. 1999 Sep 15; 18(18):5108-19.
[EMBO J. 1999]Genes Dev. 2003 Jun 1; 17(11):1415-28.
[Genes Dev. 2003]Nature. 2002 Jan 10; 415(6868):141-7.
[Nature. 2002]J Biol Chem. 2002 Aug 23; 277(34):30421-4.
[J Biol Chem. 2002]J Biol Chem. 2002 Aug 23; 277(34):30421-4.
[J Biol Chem. 2002]Chromosoma. 2004 May; 112(7):360-71.
[Chromosoma. 2004]Nature. 2000 Dec 21-28; 408(6815):1001-4.
[Nature. 2000]Mol Cell Biol. 2000 Oct; 20(19):7051-8.
[Mol Cell Biol. 2000]EMBO J. 2004 Jul 7; 23(13):2597-607.
[EMBO J. 2004]Curr Biol. 1999 Jul 15; 9(14):767-70.
[Curr Biol. 1999]EMBO J. 1999 Sep 15; 18(18):5108-19.
[EMBO J. 1999]Mol Cell Biol. 1999 Apr; 19(4):2515-26.
[Mol Cell Biol. 1999]Mol Cell Biol. 1999 Mar; 19(3):2061-8.
[Mol Cell Biol. 1999]Mol Cell. 2000 Jun; 5(6):905-15.
[Mol Cell. 2000]Mol Cell. 2003 Aug; 12(2):461-73.
[Mol Cell. 2003]Mol Cell. 2000 Jun; 5(6):917-26.
[Mol Cell. 2000]EMBO J. 1999 Sep 15; 18(18):5108-19.
[EMBO J. 1999]Mol Cell. 2000 Jun; 5(6):905-15.
[Mol Cell. 2000]Mol Cell. 2000 Jun; 5(6):917-26.
[Mol Cell. 2000]Nature. 2000 Dec 21-28; 408(6815):1001-4.
[Nature. 2000]Nature. 2000 Dec 21-28; 408(6815):1001-4.
[Nature. 2000]Nature. 2002 Jan 10; 415(6868):141-7.
[Nature. 2002]Nature. 2002 Jan 10; 415(6868):180-3.
[Nature. 2002]Cell. 2001 Sep 7; 106(5):575-84.
[Cell. 2001]Mol Cell. 2001 Feb; 7(2):283-92.
[Mol Cell. 2001]EMBO J. 2004 Oct 1; 23(19):3874-85.
[EMBO J. 2004]Nature. 2002 Jan 10; 415(6868):141-7.
[Nature. 2002]Nature. 2002 Jan 10; 415(6868):180-3.
[Nature. 2002]Mol Cell Biol. 2002 Oct; 22(20):6979-92.
[Mol Cell Biol. 2002]Mol Cell Biol. 2004 Jun; 24(11):4734-42.
[Mol Cell Biol. 2004]Mol Cell Biol. 2001 Apr; 21(8):2726-35.
[Mol Cell Biol. 2001]EMBO J. 2004 Oct 1; 23(19):3874-85.
[EMBO J. 2004]Cell. 2004 Apr 2; 117(1):17-28.
[Cell. 2004]Mol Cell Biol. 2004 Oct; 24(19):8356-65.
[Mol Cell Biol. 2004]Curr Biol. 1999 Jul 15; 9(14):767-70.
[Curr Biol. 1999]Nature. 2002 Sep 26; 419(6905):411-5.
[Nature. 2002]Mol Cell. 2000 Jun; 5(6):905-15.
[Mol Cell. 2000]Science. 2001 Aug 10; 293(5532):1142-6.
[Science. 2001]Mol Cell. 2000 Jun; 5(6):917-26.
[Mol Cell. 2000]Science. 2001 Aug 3; 293(5531):853-7.
[Science. 2001]J Biol Chem. 2002 Aug 23; 277(34):30421-4.
[J Biol Chem. 2002]Chromosoma. 2004 May; 112(7):360-71.
[Chromosoma. 2004]J Biol Chem. 2002 Aug 23; 277(34):30421-4.
[J Biol Chem. 2002]J Cell Sci. 2004 Sep 1; 117(Pt 19):4449-59.
[J Cell Sci. 2004]Curr Biol. 2001 Jun 26; 11(12):996-1000.
[Curr Biol. 2001]Nature. 2003 Oct 2; 425(6957):475-9.
[Nature. 2003]J Biol Chem. 2002 Jan 25; 277(4):2579-88.
[J Biol Chem. 2002]Genes Dev. 2003 Jun 1; 17(11):1415-28.
[Genes Dev. 2003]J Cell Sci. 2004 Sep 1; 117(Pt 19):4449-59.
[J Cell Sci. 2004]Chromosoma. 2004 May; 112(7):360-71.
[Chromosoma. 2004]Science. 1975 Oct 10; 190(4210):117-28.
[Science. 1975]Curr Biol. 2005 Apr 12; 15(7):656-60.
[Curr Biol. 2005]Proc Natl Acad Sci U S A. 2004 May 11; 101(19):7357-62.
[Proc Natl Acad Sci U S A. 2004]Mol Cell Biol. 2004 Jan; 24(2):757-64.
[Mol Cell Biol. 2004]Nat Biotechnol. 2004 Aug; 22(8):1013-6.
[Nat Biotechnol. 2004]Mol Cell. 2004 Dec 22; 16(6):979-90.
[Mol Cell. 2004]Genes Dev. 2004 Mar 15; 18(6):602-16.
[Genes Dev. 2004]Proc Natl Acad Sci U S A. 2004 Feb 10; 101(6):1644-9.
[Proc Natl Acad Sci U S A. 2004]